RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty

R. J. Friedman, B. L. Davidson, J. Heit, C. Kessler, C. G. Elliott, V. Cabanas, C. Chenault, D. Dall, D. R. Chandler, D. Drennan, M. Suchyta, M. Gohle, H. E. Groth, S. Hoff, A. Holmann, L. Murdock, T. Hyers, J. Ohar, W. M. Johnson

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

The efficacy and safety of RD heparin, a low-molecular-weight heparin, for the prevention of venous thromboembolic disease among patients managed with an elective total hip or total knee arthroplasty were compared with the efficacy and safety of warfarin in an open-label prospective, multicenter trial. Patients were randomized to receive either a fixed dose of fifty anti- factor-X(a) units of RD heparin per kilogram of body weight, administered subcutaneously twice daily, beginning postoperatively; a fixed dose of ninety anti-factor-X(a) units of RD heparin per kilogram of body weight, administered subcutaneously once daily, beginning postoperatively; or five milligrams of warfarin, administered orally preoperatively, followed by a daily adjusted dose of warfarin to prolong the prothrombin time ratio to 1.2 to 1.5. The primary measure of efficacy was contrast venography of the treated limb, performed by local radiologists blinded to the type of treatment that had been assigned. Nine hundred and sixty-nine patients had a complete assessment for the presence of deep-vein thrombosis. The over-all rates of venous thromboembolic disease were 16 per cent (95 per cent confidence interval, 13 to 21 per cent) (fifty-three) for the 328 patients who received RD heparin twice daily, 21 per cent (95 per cent confidence interval, 17 to 26 per cent) (sixty-eight) for the 320 patients who received RD heparin once daily, and 27 per cent (95 per cent confidence interval, 22 to 32 per cent) (eighty-seven) for the 321 patients who received warfarin (p < 0.001 for RD heparin administered twice daily compared with warfarin; p = 0.13 for RD heparin administered once daily compared with warfarin). Compared with warfarin, RD heparin administered twice daily and RD heparin administered once daily reduced the risk of venous thromboembolic disease by 41 per cent (95 per cent confidence interval, 20 to 56 per cent) and 18 per cent (95 per cent confidence interval, -6 to 37 per cent), respectively. The rates of venous thromboembolic disease after 523 total hip arthroplasties were 8, 14, and 14 per cent for the patients who received RD heparin twice daily, those who received it once daily, and those who received warfarin (p = 0.07 for RD heparin administered twice daily compared with warfarin; p = 0.82 for RD heparin administered once daily compared with warfarin). The rates after 446 total knee arthroplasties were 26, 30, and 43 per cent, respectively (p = 0.004 for RD heparin administered twice daily compared with warfarin; p = 0.04 for RD heparin administered once daily compared with warfarin). A fixed dose of fifty anti-factor-X(a) units of RD heparin per kilogram of body weight administered subcutaneously twice daily, beginning postoperatively, appeared more effective than low-dose warfarin for the prevention of venous thromboembolic disease following a major orthopaedic procedure on the lower limb. For the patients who had had a total hip arthroplasty, RD heparin administered twice daily and warfarin were equally effective and safe. For the patients who had had a total knee arthroplasty, RD heparin administered twice daily was significantly more effective than warfarin, although the rate of deep-vein thrombosis remained substantial. There was no difference between RD heparin administered twice daily and warfarin with regard to the rate of clinically important bleeding events. Both regimens of RD heparin and the warfarin were equally safe. RD heparin does not require daily adjustments of the dose or laboratory monitoring, which makes it easier to administer than warfarin.

Original languageEnglish (US)
Pages (from-to)1174-1185
Number of pages12
JournalJournal of Bone and Joint Surgery - Series A
Volume76
Issue number8
StatePublished - 1994
Externally publishedYes

Fingerprint

Knee Replacement Arthroplasties
Warfarin
Heparin
Hip
Factor X
Confidence Intervals
Body Weight
Venous Thrombosis
Arthroplasty
Orthopedic Procedures
Safety

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Friedman, R. J., Davidson, B. L., Heit, J., Kessler, C., Elliott, C. G., Cabanas, V., ... Johnson, W. M. (1994). RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. Journal of Bone and Joint Surgery - Series A, 76(8), 1174-1185.

RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. / Friedman, R. J.; Davidson, B. L.; Heit, J.; Kessler, C.; Elliott, C. G.; Cabanas, V.; Chenault, C.; Dall, D.; Chandler, D. R.; Drennan, D.; Suchyta, M.; Gohle, M.; Groth, H. E.; Hoff, S.; Holmann, A.; Murdock, L.; Hyers, T.; Ohar, J.; Johnson, W. M.

In: Journal of Bone and Joint Surgery - Series A, Vol. 76, No. 8, 1994, p. 1174-1185.

Research output: Contribution to journalArticle

Friedman, RJ, Davidson, BL, Heit, J, Kessler, C, Elliott, CG, Cabanas, V, Chenault, C, Dall, D, Chandler, DR, Drennan, D, Suchyta, M, Gohle, M, Groth, HE, Hoff, S, Holmann, A, Murdock, L, Hyers, T, Ohar, J & Johnson, WM 1994, 'RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty', Journal of Bone and Joint Surgery - Series A, vol. 76, no. 8, pp. 1174-1185.
Friedman, R. J. ; Davidson, B. L. ; Heit, J. ; Kessler, C. ; Elliott, C. G. ; Cabanas, V. ; Chenault, C. ; Dall, D. ; Chandler, D. R. ; Drennan, D. ; Suchyta, M. ; Gohle, M. ; Groth, H. E. ; Hoff, S. ; Holmann, A. ; Murdock, L. ; Hyers, T. ; Ohar, J. ; Johnson, W. M. / RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. In: Journal of Bone and Joint Surgery - Series A. 1994 ; Vol. 76, No. 8. pp. 1174-1185.
@article{b353740921fe440086b9d7a03f9673cc,
title = "RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty",
abstract = "The efficacy and safety of RD heparin, a low-molecular-weight heparin, for the prevention of venous thromboembolic disease among patients managed with an elective total hip or total knee arthroplasty were compared with the efficacy and safety of warfarin in an open-label prospective, multicenter trial. Patients were randomized to receive either a fixed dose of fifty anti- factor-X(a) units of RD heparin per kilogram of body weight, administered subcutaneously twice daily, beginning postoperatively; a fixed dose of ninety anti-factor-X(a) units of RD heparin per kilogram of body weight, administered subcutaneously once daily, beginning postoperatively; or five milligrams of warfarin, administered orally preoperatively, followed by a daily adjusted dose of warfarin to prolong the prothrombin time ratio to 1.2 to 1.5. The primary measure of efficacy was contrast venography of the treated limb, performed by local radiologists blinded to the type of treatment that had been assigned. Nine hundred and sixty-nine patients had a complete assessment for the presence of deep-vein thrombosis. The over-all rates of venous thromboembolic disease were 16 per cent (95 per cent confidence interval, 13 to 21 per cent) (fifty-three) for the 328 patients who received RD heparin twice daily, 21 per cent (95 per cent confidence interval, 17 to 26 per cent) (sixty-eight) for the 320 patients who received RD heparin once daily, and 27 per cent (95 per cent confidence interval, 22 to 32 per cent) (eighty-seven) for the 321 patients who received warfarin (p < 0.001 for RD heparin administered twice daily compared with warfarin; p = 0.13 for RD heparin administered once daily compared with warfarin). Compared with warfarin, RD heparin administered twice daily and RD heparin administered once daily reduced the risk of venous thromboembolic disease by 41 per cent (95 per cent confidence interval, 20 to 56 per cent) and 18 per cent (95 per cent confidence interval, -6 to 37 per cent), respectively. The rates of venous thromboembolic disease after 523 total hip arthroplasties were 8, 14, and 14 per cent for the patients who received RD heparin twice daily, those who received it once daily, and those who received warfarin (p = 0.07 for RD heparin administered twice daily compared with warfarin; p = 0.82 for RD heparin administered once daily compared with warfarin). The rates after 446 total knee arthroplasties were 26, 30, and 43 per cent, respectively (p = 0.004 for RD heparin administered twice daily compared with warfarin; p = 0.04 for RD heparin administered once daily compared with warfarin). A fixed dose of fifty anti-factor-X(a) units of RD heparin per kilogram of body weight administered subcutaneously twice daily, beginning postoperatively, appeared more effective than low-dose warfarin for the prevention of venous thromboembolic disease following a major orthopaedic procedure on the lower limb. For the patients who had had a total hip arthroplasty, RD heparin administered twice daily and warfarin were equally effective and safe. For the patients who had had a total knee arthroplasty, RD heparin administered twice daily was significantly more effective than warfarin, although the rate of deep-vein thrombosis remained substantial. There was no difference between RD heparin administered twice daily and warfarin with regard to the rate of clinically important bleeding events. Both regimens of RD heparin and the warfarin were equally safe. RD heparin does not require daily adjustments of the dose or laboratory monitoring, which makes it easier to administer than warfarin.",
author = "Friedman, {R. J.} and Davidson, {B. L.} and J. Heit and C. Kessler and Elliott, {C. G.} and V. Cabanas and C. Chenault and D. Dall and Chandler, {D. R.} and D. Drennan and M. Suchyta and M. Gohle and Groth, {H. E.} and S. Hoff and A. Holmann and L. Murdock and T. Hyers and J. Ohar and Johnson, {W. M.}",
year = "1994",
language = "English (US)",
volume = "76",
pages = "1174--1185",
journal = "Journal of Bone and Joint Surgery - American Volume",
issn = "0021-9355",
publisher = "Journal of Bone and Joint Surgery Inc.",
number = "8",

}

TY - JOUR

T1 - RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty

AU - Friedman, R. J.

AU - Davidson, B. L.

AU - Heit, J.

AU - Kessler, C.

AU - Elliott, C. G.

AU - Cabanas, V.

AU - Chenault, C.

AU - Dall, D.

AU - Chandler, D. R.

AU - Drennan, D.

AU - Suchyta, M.

AU - Gohle, M.

AU - Groth, H. E.

AU - Hoff, S.

AU - Holmann, A.

AU - Murdock, L.

AU - Hyers, T.

AU - Ohar, J.

AU - Johnson, W. M.

PY - 1994

Y1 - 1994

N2 - The efficacy and safety of RD heparin, a low-molecular-weight heparin, for the prevention of venous thromboembolic disease among patients managed with an elective total hip or total knee arthroplasty were compared with the efficacy and safety of warfarin in an open-label prospective, multicenter trial. Patients were randomized to receive either a fixed dose of fifty anti- factor-X(a) units of RD heparin per kilogram of body weight, administered subcutaneously twice daily, beginning postoperatively; a fixed dose of ninety anti-factor-X(a) units of RD heparin per kilogram of body weight, administered subcutaneously once daily, beginning postoperatively; or five milligrams of warfarin, administered orally preoperatively, followed by a daily adjusted dose of warfarin to prolong the prothrombin time ratio to 1.2 to 1.5. The primary measure of efficacy was contrast venography of the treated limb, performed by local radiologists blinded to the type of treatment that had been assigned. Nine hundred and sixty-nine patients had a complete assessment for the presence of deep-vein thrombosis. The over-all rates of venous thromboembolic disease were 16 per cent (95 per cent confidence interval, 13 to 21 per cent) (fifty-three) for the 328 patients who received RD heparin twice daily, 21 per cent (95 per cent confidence interval, 17 to 26 per cent) (sixty-eight) for the 320 patients who received RD heparin once daily, and 27 per cent (95 per cent confidence interval, 22 to 32 per cent) (eighty-seven) for the 321 patients who received warfarin (p < 0.001 for RD heparin administered twice daily compared with warfarin; p = 0.13 for RD heparin administered once daily compared with warfarin). Compared with warfarin, RD heparin administered twice daily and RD heparin administered once daily reduced the risk of venous thromboembolic disease by 41 per cent (95 per cent confidence interval, 20 to 56 per cent) and 18 per cent (95 per cent confidence interval, -6 to 37 per cent), respectively. The rates of venous thromboembolic disease after 523 total hip arthroplasties were 8, 14, and 14 per cent for the patients who received RD heparin twice daily, those who received it once daily, and those who received warfarin (p = 0.07 for RD heparin administered twice daily compared with warfarin; p = 0.82 for RD heparin administered once daily compared with warfarin). The rates after 446 total knee arthroplasties were 26, 30, and 43 per cent, respectively (p = 0.004 for RD heparin administered twice daily compared with warfarin; p = 0.04 for RD heparin administered once daily compared with warfarin). A fixed dose of fifty anti-factor-X(a) units of RD heparin per kilogram of body weight administered subcutaneously twice daily, beginning postoperatively, appeared more effective than low-dose warfarin for the prevention of venous thromboembolic disease following a major orthopaedic procedure on the lower limb. For the patients who had had a total hip arthroplasty, RD heparin administered twice daily and warfarin were equally effective and safe. For the patients who had had a total knee arthroplasty, RD heparin administered twice daily was significantly more effective than warfarin, although the rate of deep-vein thrombosis remained substantial. There was no difference between RD heparin administered twice daily and warfarin with regard to the rate of clinically important bleeding events. Both regimens of RD heparin and the warfarin were equally safe. RD heparin does not require daily adjustments of the dose or laboratory monitoring, which makes it easier to administer than warfarin.

AB - The efficacy and safety of RD heparin, a low-molecular-weight heparin, for the prevention of venous thromboembolic disease among patients managed with an elective total hip or total knee arthroplasty were compared with the efficacy and safety of warfarin in an open-label prospective, multicenter trial. Patients were randomized to receive either a fixed dose of fifty anti- factor-X(a) units of RD heparin per kilogram of body weight, administered subcutaneously twice daily, beginning postoperatively; a fixed dose of ninety anti-factor-X(a) units of RD heparin per kilogram of body weight, administered subcutaneously once daily, beginning postoperatively; or five milligrams of warfarin, administered orally preoperatively, followed by a daily adjusted dose of warfarin to prolong the prothrombin time ratio to 1.2 to 1.5. The primary measure of efficacy was contrast venography of the treated limb, performed by local radiologists blinded to the type of treatment that had been assigned. Nine hundred and sixty-nine patients had a complete assessment for the presence of deep-vein thrombosis. The over-all rates of venous thromboembolic disease were 16 per cent (95 per cent confidence interval, 13 to 21 per cent) (fifty-three) for the 328 patients who received RD heparin twice daily, 21 per cent (95 per cent confidence interval, 17 to 26 per cent) (sixty-eight) for the 320 patients who received RD heparin once daily, and 27 per cent (95 per cent confidence interval, 22 to 32 per cent) (eighty-seven) for the 321 patients who received warfarin (p < 0.001 for RD heparin administered twice daily compared with warfarin; p = 0.13 for RD heparin administered once daily compared with warfarin). Compared with warfarin, RD heparin administered twice daily and RD heparin administered once daily reduced the risk of venous thromboembolic disease by 41 per cent (95 per cent confidence interval, 20 to 56 per cent) and 18 per cent (95 per cent confidence interval, -6 to 37 per cent), respectively. The rates of venous thromboembolic disease after 523 total hip arthroplasties were 8, 14, and 14 per cent for the patients who received RD heparin twice daily, those who received it once daily, and those who received warfarin (p = 0.07 for RD heparin administered twice daily compared with warfarin; p = 0.82 for RD heparin administered once daily compared with warfarin). The rates after 446 total knee arthroplasties were 26, 30, and 43 per cent, respectively (p = 0.004 for RD heparin administered twice daily compared with warfarin; p = 0.04 for RD heparin administered once daily compared with warfarin). A fixed dose of fifty anti-factor-X(a) units of RD heparin per kilogram of body weight administered subcutaneously twice daily, beginning postoperatively, appeared more effective than low-dose warfarin for the prevention of venous thromboembolic disease following a major orthopaedic procedure on the lower limb. For the patients who had had a total hip arthroplasty, RD heparin administered twice daily and warfarin were equally effective and safe. For the patients who had had a total knee arthroplasty, RD heparin administered twice daily was significantly more effective than warfarin, although the rate of deep-vein thrombosis remained substantial. There was no difference between RD heparin administered twice daily and warfarin with regard to the rate of clinically important bleeding events. Both regimens of RD heparin and the warfarin were equally safe. RD heparin does not require daily adjustments of the dose or laboratory monitoring, which makes it easier to administer than warfarin.

UR - http://www.scopus.com/inward/record.url?scp=0028085542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028085542&partnerID=8YFLogxK

M3 - Article

VL - 76

SP - 1174

EP - 1185

JO - Journal of Bone and Joint Surgery - American Volume

JF - Journal of Bone and Joint Surgery - American Volume

SN - 0021-9355

IS - 8

ER -